S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
Authors:
Open Access
- 8 August 2023
- journal article
- abstracts
- Published by Wiley in HemaSphere
- Vol. 7 (S3) , e10648ed